71312-90-8

Basic information

• Product Name: C₁₇H₁₄N₂O
• Synonyms: C₁₇H₁₄N₂O
• CAS NO: 71312-90-8
• Molecular Weight: 262.311
• Mol File: 71312-90-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: C₁₇H₁₄N₂O(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₇H₁₄N₂O(71312-90-8)
• EPA Substance Registry System: C₁₇H₁₄N₂O(71312-90-8)

Safety Data

• Hazardous Substances Data: 71312-90-8(Hazardous Substances Data)

Upstream product

• 7251-61-8 2-methylquinoxaline 
• 2393-23-9 4-methoxy-benzylamine 
• 91-19-0 2,3-diethynylquinoxaline 
• 6935-29-1 quinoxaline-N-oxide 
• 123-11-5 4-methoxy-benzaldehyde 

Downstream Products

• 1374162-19-2 (S)-2-[2-(4-methoxyphenyl)ethyl]-1,2,3,4-tetrahydroquinoxaline 

Relevant articles and documents

NaCl as Catalyst and Water as Solvent: Highly E-Selective Olefination of Methyl Substituted N-Heteroarenes with Benzyl Amines and Alcohols

Oxidative coupling of benzylamines and alcohols with methyl substituted N-heteroarenes such as quinolines and quinoxalines has been achieved using chloride, a sea abundant anion as the catalyst for practical synthesis of a wide range of E-disubstituted olefins in aqueous medium. Detailed mechanistic studies and control experiments were carried out to deduce the reaction mechanism which indicated that in situ formed ClO2- is the active form of the catalyst. We have successfully carried out a 1 g scale reaction using this methodology, and five pharmaceutically relevant conjugated olefins were also synthesized by this method in moderate to good yields.

Palladium-catalyzed C–H alkenylation of quinoxaline N-oxide enabled by a mono-N-protected amino acid

The efficient alkenylation of quinoxaline N-oxide was achieved via Pd-catalyzed C–H activation, using the assistance of a mono-N-protected amino acid. Further deoxygenation of the 2-styrylquinoxaline-N-oxides yielded the corresponding styrylquinoxaline de

Utilities of olefin derivatives

Compounds having an activity to enhance the expression of apoAI are provided. Compounds of formula (I): in which Ar1 and Ar2 are independently a phenyl, naphthyl, or monocyclic or bicyclic aromatic heterocyclic group, which may be optionally substituted; —X— is —N═CZ2-, —CY2═CZ2-, —CY2Y3—CHZ2-, —S—, —O—, or the like; Y1, Y2, Y3, Z1 and Z2 are independently a hydrogen, a halogen, a lower alkyl, a phenyl, or the like; Z1 and Z2 may be independently a linker group that may combine with Ar2 and Ar1 to form a condensed ring; m is 0 or 1, and n is 0 to 2; a prodrug thereof, a pharmaceutically acceptable salt or solvate of them; are disclosed.